Literature DB >> 14625090

Expression of gec1/GABARAPL1 versus GABARAP mRNAs in human: predominance of gec1/GABARAPL1 in the central nervous system.

Christophe Nemos1, Virginie Mansuy, Sandrine Vernier-Magnin, Annick Fraichard, Michèle Jouvenot, Régis Delage-Mourroux.   

Abstract

GABARAP and gec1/GABARAPL1 genes encode very similar proteins belonging to a new microtubule-associated protein (MAP) family. These proteins could participate in a complex clustering, targeting and/or degrading the GABA(A) receptors on post-synaptic membrane of neurons. Using specific cDNA probes, we investigated the differential expression of both genes in 76 human tissues. Against all odds, gec1/GABARAPL1 was more expressed than GABARAP in the central nervous system (CNS), while GABARAP was more expressed in endocrine glands.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14625090     DOI： 10.1016/j.molbrainres.2003.09.011

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN： 0169-328X


  26 in total

1.  Starch Binding Domain-containing Protein 1 Plays a Dominant Role in Glycogen Transport to Lysosomes in Liver.

Authors:  Tao Sun; Haiqing Yi; Chunyu Yang; Priya S Kishnani; Baodong Sun
Journal:  J Biol Chem       Date:  2016-06-29       Impact factor: 5.157

2.  Truncation of histone H2A's C-terminal tail, as is typical for Ni(II)-assisted specific peptide bond hydrolysis, has gene expression altering effects.

Authors:  Aldona A Karaczyn; Robert Y S Cheng; Gregory S Buzard; James Hartley; Dominic Esposito; Kazimierz S Kasprzak
Journal:  Ann Clin Lab Sci       Date:  2009       Impact factor: 1.256

3.  Effects of C-terminal modifications of GEC1 protein and gamma-aminobutyric acid type A (GABA(A)) receptor-associated protein (GABARAP), two microtubule-associated proteins, on kappa opioid receptor expression.

Authors:  Chongguang Chen; Yulin Wang; Peng Huang; Lee-Yuan Liu-Chen
Journal:  J Biol Chem       Date:  2011-03-09       Impact factor: 5.157

Review 4.  The evolutionary and functional divergence of the Atg8 autophagy protein superfamily.

Authors:  Virginia B Varga; Fanni Keresztes; Tímea Sigmond; Tibor Vellai; Tibor Kovács
Journal:  Biol Futur       Date:  2022-06-22

Review 5.  Unlocking the gate to GABARAPL2.

Authors:  Jennifer C Y Chan; Sharon M Gorski
Journal:  Biol Futur       Date:  2022-04-29

6.  High expression of gabarapl1 is associated with a better outcome for patients with lymph node-positive breast cancer.

Authors:  A Berthier; S Seguin; A J Sasco; J Y Bobin; G De Laroche; J Datchary; S Saez; C Rodriguez-Lafrasse; F Tolle; A Fraichard; M Boyer-Guittaut; M Jouvenot; R Delage-Mourroux; F Descotes
Journal:  Br J Cancer       Date:  2010-03-02       Impact factor: 7.640

7.  The trafficking protein GABARAP binds to and enhances plasma membrane expression and function of the angiotensin II type 1 receptor.

Authors:  Julia L Cook; Richard N Re; Dawn L deHaro; Jennifer M Abadie; Michelle Peters; Jawed Alam
Journal:  Circ Res       Date:  2008-05-22       Impact factor: 17.367

8.  The role of GABARAPL1/GEC1 in autophagic flux and mitochondrial quality control in MDA-MB-436 breast cancer cells.

Authors:  Michaël Boyer-Guittaut; Laura Poillet; Qiuli Liang; Elodie Bôle-Richard; Xiaosen Ouyang; Gloria A Benavides; Fatima-Zahra Chakrama; Annick Fraichard; Victor M Darley-Usmar; Gilles Despouy; Michèle Jouvenot; Régis Delage-Mourroux; Jianhua Zhang
Journal:  Autophagy       Date:  2014-06       Impact factor: 16.016

9.  GEC1-kappa opioid receptor binding involves hydrophobic interactions: GEC1 has chaperone-like effect.

Authors:  Yong Chen; Chongguang Chen; Evangelia Kotsikorou; Diane L Lynch; Patricia H Reggio; Lee-Yuan Liu-Chen
Journal:  J Biol Chem       Date:  2008-11-11       Impact factor: 5.157

10.  Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome.

Authors:  N Kaushik; D Fear; S C M Richards; C R McDermott; E F Nuwaysir; P Kellam; T J Harrison; R J Wilkinson; D A J Tyrrell; S T Holgate; J R Kerr
Journal:  J Clin Pathol       Date:  2005-08       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.